Pds biotech announces interim data demonstrates 12-month survival rate of 87% with pds0101 in combination with keytruda® (pembrolizumab) for head and neck cancer patients

Interim data being presented at asco 2023 annual meeting demonstrated median progression-free survival (pfs) of 10.4 months demonstrated 12-month overall survival (os) rate of 87.1% a disease control rate (disease stabilization or tumor shrinkage) of 70.6% median overall survival not yet met company to host conference call and webcast on june 6, 2023, at 8:00 am et florham park, n.j., may 25, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced promising interim data from the versatile-002 (nct04260126) phase 2 clinical trial investigating pds0101 in combination with merck's anti-pd-1 therapy, keytruda® (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus (hpv)16-positive head and neck cancer.
PDSB Ratings Summary
PDSB Quant Ranking